Sexcord/ stromal ovarian tumors other imaging findings

Jump to navigation Jump to search

Sexcord/ stromal ovarian tumors Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sexcord/ Stromal Ovarian Tumors from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sexcord/ stromal ovarian tumors other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sexcord/ stromal ovarian tumors other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sexcord/ stromal ovarian tumors other imaging findings

CDC on Sexcord/ stromal ovarian tumors other imaging findings

Sexcord/ stromal ovarian tumors other imaging findings in the news

Blogs on Sexcord/ stromal ovarian tumors other imaging findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Sexcord/ stromal ovarian tumors other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Maneesha Nandimandalam, M.B.B.S.[2]

Overview

PET-CT may be helpful in the diagnosis of sexcord/ stromal ovarian tumors. On fluorodeoxyglucose-positron emission tomography/computed tomography malignant ovarian tumors generally have intense uptake, whereas tumors with a small solid content show decreased uptake.

Other Imaging Findings

PET-CT scan and macroscopic findings in a recurrent patient (case 11). (A) PET-CT scan before treatment; a black arrow points to the metastatic tumor in the left portion of the fourth lumbar vertebra. (B) PET-CT scan after treatment. (C) and (D) show the retroperitoneal tumor fused by several para-aortic lymph node,Qian Q, You Y, Yang J, et al. Management and prognosis of patients with ovarian sex cord tumor with annular tubules: a retrospective study. BMC Cancer. 2015;15:270. Published 2015 Apr 12. doi:10.1186/s12885-015-1277-y,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408581/

References

  1. ↑ Qian Q, You Y, Yang J, Cao D, Zhu Z, Wu M, Chen J, Lang J, Shen K (April 2015). "Management and prognosis of patients with ovarian sex cord tumor with annular tubules: a retrospective study". BMC Cancer. 15: 270. doi:10.1186/s12885-015-1277-y. PMID 25886261.
  2. ↑ Bristow RE, Simpkins F, Pannu HK, Fishman EK, Montz FJ (April 2002). "Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer". Gynecol. Oncol. 85 (1): 196–200. doi:10.1006/gyno.2002.6611. PMID 11925145.
  3. ↑ Tomimatsu T, Fukuda Y, Mimura K, Yoshino K, Kato H, Tsuboyama T, Hori Y, Kimura T (December 2016). "Intense fluorodeoxyglucose uptake by a benign sclerosing stromal tumor of the ovary". Taiwan J Obstet Gynecol. 55 (6): 893–894. doi:10.1016/j.tjog.2016.03.005. PMID 28040143.
  4. ↑ Matsutani H, Nakai G, Yamada T, Yamamoto K, Ohmichi M, Narumi Y (December 2018). "Diversity of imaging features of ovarian sclerosing stromal tumors on MRI and PET-CT: a case report and literature review". J Ovarian Res. 11 (1): 101. doi:10.1186/s13048-018-0473-1. PMC 6302382. PMID 30572921.
  5. ↑ Kitajima K, Ueno Y, Maeda T, Murakami K, Kaji Y, Kita M, Suzuki K, Sugimura K (November 2011). "Spectrum of fluorodeoxyglucose-positron emission tomography/computed tomography and magnetic resonance imaging findings of ovarian tumors". Jpn J Radiol. 29 (9): 605–8. doi:10.1007/s11604-011-0610-x. PMID 21956364.

Template:WH Template:WS